Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Increased secretory leukoprotease inhibitor in patients with nonsmall celllung carcinoma
Autore:
Ameshima, S; Ishizaki, T; Demura, Y; Imamura, Y; Miyamori, I; Mitsuhashi, H;
Indirizzi:
Fukui Med Univ, Dept Internal Med, Matsuoka, Fukui 9101193, Japan Fukui Med Univ Matsuoka Fukui Japan 9101193 atsuoka, Fukui 9101193, Japan Fukui Med Univ, Dept Pathol, Fukui, Japan Fukui Med Univ Fukui JapanFukui Med Univ, Dept Pathol, Fukui, Japan Teijin Ltd, Inst Biomed Res, Tokyo, Japan Teijin Ltd Tokyo JapanTeijin Ltd, Inst Biomed Res, Tokyo, Japan
Titolo Testata:
CANCER
fascicolo: 7, volume: 89, anno: 2000,
pagine: 1448 - 1456
SICI:
0008-543X(20001001)89:7<1448:ISLIIP>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
LEUKOCYTE PROTEASE INHIBITOR; PROTEINASE-INHIBITOR; LOCAL INCREASE; ELASTASE; ANTILEUKOPROTEASE; ANTIPROTEASE; LOCALIZATION; IMBALANCE; CANCER;
Keywords:
secretory leukoprotease inhibitor (SLPI); nonsmall cell lung carcinoma (NSCLC); small cell lung carcinoma (SCLC); tumor marker; immunohistochemistry;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: Ameshima, S Fukui Med Univ, Dept Internal Med, Matsuoka, Fukui 9101193, Japan Fukui Med Univ Matsuoka Fukui Japan 9101193 ui 9101193, Japan
Citazione:
S. Ameshima et al., "Increased secretory leukoprotease inhibitor in patients with nonsmall celllung carcinoma", CANCER, 89(7), 2000, pp. 1448-1456

Abstract

BACKGROUND. It is well known that acute pulmonary inflammation, such as that observed in pneumonia, elevates secretory leukoprotease inhibitor (SLPI)levels in serum. A previous report indicated that serum SLPI levels in lung carcinoma patients with concurrent pneumonia were significantly higher than in those in patients whose disease was unaccompanied by pneumonia or in healthy subjects. The authors hypothesized that serum SLPI may increase in patients with lung carcinoma, even carcinoma occurring without pneumonia, and that cells in lung carcinoma might produce SLPI. METHODS. Serum SLPI levels in 58 patients with primary lung carcinoma unaccompanied by pneumonia and in 42 healthy subjects were measured by an enzyme immunoassay. Twenty-four specimens from 24 of the patients with primary lung carcinoma also were examined immunohistochemically using the rabbit antihuman SLPI antibody. RESULTS. The results of the current study confirmed that the serum levels of SLPI in patients with primary lung carcinoma were higher than those in healthy subjects, and further found there was no significant correlation between serum SLPI levels and C-reactive protein in lung carcinoma patients without pneumonia. When classifying primary lung carcinoma by its histology, SLPI levels in patients with adenocarcinoma and squamous cell carcinoma were significantly higher than in those in patients with small cell lung carcinoma (SCLC). In patients with nonsmall cell lung carcinoma (NSCLC), the SLPI levels in the advanced group (International Union Against Cancer Stages III and IV disease; n = 35) were significantly elevated compared with the nonadvanced group (Stages I and II disease; n = 12), and such elevated SLPI levels were reduced in some cases by an efficient response to surgical therapy or chemotherapy. Immunohistochemical studies showed that all the NSCLC tissues were stained with anti-human SLPI antibody, whereas staining was notnoted in any of the SCLC tissues. CONCLUSIONS. The authors believe that the findings of the current study demonstrate that cells of NSCLC produce SLPI. Furthermore, they suggest that serum SLPI levels in serum may be a helpful marker in patients with NSCLC unaccompanied by pneumonia, and that SLPI also could be used as an immunohistochemical marker to distinguish between NSCLC and SCLC. Cancer 2000;89:1448-56. (C) 2000 American Cancer Society.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 10:08:38